About Brian

Brian McMahon is a clinical Hepatologist, Medical, and Research Director at the Liver Disease and Viral Hepatitis Program at Alaska Native Medical Center. He coordinated programs to eradicate transmission hepatitis B (HBV) and hepatitis A (HAV) in the Alaska Native Population. He and his colleagues conduct research in the outcome and treatment of HBV, hepatitis C (HCV) and long-term protection of HAV and HBV vaccines. He is Clinical Professor of Medicine at University of Washington and an Auxiliary Professor at the University of Alaska WWAMI Medical Schools He was co author of the AASLD Practice Guideline on Chronic Hepatitis B 2001 to 2009, on the methodology committee for the 2016 AASLD Guidelines and the writing committee for the 2017 AASLD supplemental Guideline. He was co-chair of the WHO hepatitis B Guidelines Committee. He has also participated in establishing model programs for management of HBV/HIV co-infection and HBV monoinfection with the CDC Foundation since 2008.

This speaker will be presenting at the following session(s)

  • Delivering high quality hepatitis services

    Ballroom 4

    Day: 2 November

    Time: 14:00

    Chair: Liudmyla Maistat, Medicines Patent Pool and Prof. Njoya Oudou, Research Laboratory on Viral Hepatitis and Health Communication

    Presentations:

    • Australia hepatitis service delivery model.
    • Prof. Margaret Hellard, Burnet Institute, The Alfred Hospital and Monash University, Australia
    • HCV testing, treatment and care of people who inject drugs
    • Abigael Lukhwaro, Médecins du Monde
      Sergii Filippovych, Alliance for Public Health
      Prof. David Goldberg, Health Protection Scotland
    • Integrating hepatitis into public health services.
      Prof. Olga Golubovska, Bogomolets National Medical University and Ministry of Health, Ukraine
    • HBV services and indigenous people.
    • Dr. Brian McMahon, Alaska Native Tribal Health Consortium
    • Q & A session.

    Session objectives:

    • Review examples of service delivery models for different population groups.
    • Discuss gaps in HBV vaccination, HBV and HCV testing, diagnosis, treatment and care cascade for key populations in different settings and possible solutions to filling in the gaps.
    • Assess the role of case management; peer-to-peer support in community-based or community oriented service delivery.
  • Liver societies' role towards viral hepatitis elimination

    Matisse

    Day: 2 November

    Time: 08:00

    Topics to be discussed:

    • Prevention of mother to child transmission of HBV and strategies to increase HBV vaccine coverage (in particular birth dose coverage) and antiviral therapy for highly viremic HBsAg+ mothers.
    • Improving diagnosis of persons chronically infected with HBV or HCV.
    • Improving linkage to care of persons diagnosed to have chronic HBV or HCV, in particular vulnerable populations and persons living in rural areas.
    • Improving access to antiviral treatment of persons with chronic HBV or HCV.